Name: Latest research reports of Biocon Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Biocon Ltd.
Rating: 5
Author: Motilal Oswal

Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
08 Aug 2025	Biocon	Motilal Oswal Target	380.40	410.00	343.35 (10.79%)	7.78	Buy	pdf post cache	Broker Report Temporary headwinds in generics weigh on 1Q Motilal Oswal Biocon (BIOS) reported lower-than-expected financial performance in 1QFY26, affected mainly by a sharp reduction in generics sales and increased opex related to new facilities. pdf Copy Link Share on Share on Share on Share on Alert
09 Aug 2025	Biocon	ICICI Securities Limited Target	380.40	270.00	343.35 (10.79%)	29.02	Sell	pdf post cache	Broker Report Margin pressure persists ICICI Securities Limited Biocon’s Q1FY26 performance was marred by operating cost of new facilities for generic division and lower-thananticipated margins in biologics division. pdf Copy Link Share on Share on Share on Share on Alert
03 Oct 2025	Biocon	Geojit BNP Paribas Reco Target	380.40	312.00	352.25 (7.99%)	17.98	Sell	pdf post cache	Broker Report BIOCON LTD Geojit BNP Paribas *over or under performance to benchmark index Biocon Ltd is a biopharmaceutical company that develops therapies for chronic diseases such as autoimmune, cancer and diabetes. The company has developed and introduced novel biologics, biosimilars, differentiated small molecules and affordable recombinant human insulin and analogues. In Q1FY26, Biocon's consolidated revenue grew 14.8% YoY to Rs. 3,942cr, driven... pdf Copy Link Share on Share on Share on Share on Alert

Highest Upside

Recent broker research reports which have the highest upside or maximum gain potential. Both buy and sell reports with maximum gain with respect to their targets are available.

Temporary headwinds in generics weigh on 1Q

Margin pressure persists

BIOCON LTD

Advisor Screeners